JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Adaptive Biotechnologies Corp

Slēgts

12.13 -0.25

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

11.9

Max

12.65

Galvenie mērījumi

By Trading Economics

Ienākumi

3.9M

-30M

Pārdošana

5M

52M

Peļņas marža

-56.881

Darbinieki

619

EBITDA

-3.3M

-30M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+13.17% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 6. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

503M

1.7B

Iepriekšējā atvēršanas cena

12.38

Iepriekšējā slēgšanas cena

12.13

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bullish Evidence

Adaptive Biotechnologies Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 11. aug. 17:49 UTC

Galvenie tirgus virzītāji

180 Life Sciences Stock Jumps on $156 Million Notes Sale

2025. g. 11. aug. 17:18 UTC

Galvenie tirgus virzītāji

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

2025. g. 11. aug. 16:25 UTC

Peļņas

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

2025. g. 11. aug. 23:50 UTC

Tirgus saruna

Nikkei May Rise as Yen Weakens -- Market Talk

2025. g. 11. aug. 23:42 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 11. aug. 23:42 UTC

Tirgus saruna

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

2025. g. 11. aug. 23:36 UTC

Tirgus saruna

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2025. g. 11. aug. 23:32 UTC

Tirgus saruna

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

2025. g. 11. aug. 23:02 UTC

Tirgus saruna

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

2025. g. 11. aug. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 11. aug. 20:37 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

2025. g. 11. aug. 20:37 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Bakkt Holdings 2Q Rev $577.9M >BKKT

2025. g. 11. aug. 20:37 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement 2Q Rev $25.8M >EXOD

2025. g. 11. aug. 20:14 UTC

Tirgus saruna

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

2025. g. 11. aug. 19:12 UTC

Tirgus saruna

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

2025. g. 11. aug. 18:56 UTC

Tirgus saruna

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

2025. g. 11. aug. 18:31 UTC

Tirgus saruna

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

2025. g. 11. aug. 17:43 UTC

Tirgus saruna

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

2025. g. 11. aug. 17:28 UTC

Tirgus saruna

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

2025. g. 11. aug. 17:16 UTC

Tirgus saruna

Commodity Longs Fall to 11-Month Low -- Market Talk

2025. g. 11. aug. 16:42 UTC

Iegādes, apvienošanās, pārņemšana

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

2025. g. 11. aug. 16:27 UTC

Iegādes, apvienošanās, pārņemšana

BBVA Says Sabadell Offer Remains in Effect

2025. g. 11. aug. 16:26 UTC

Iegādes, apvienošanās, pārņemšana

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

2025. g. 11. aug. 16:25 UTC

Iegādes, apvienošanās, pārņemšana

Banco de Sabadell Announced TSB Sale on July 1

2025. g. 11. aug. 16:25 UTC

Iegādes, apvienošanās, pārņemšana

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Salīdzinājums

Cenas izmaiņa

Adaptive Biotechnologies Corp Prognoze

Cenas mērķis

By TipRanks

13.17% augšup

Prognoze 12 mēnešiem

Vidējais 13.75 USD  13.17%

Augstākais 15 USD

Zemākais 11 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Adaptive Biotechnologies Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

6

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

8.81 / 10.18Atbalsts un pretestība

Īstermiņā

Very Strong Bullish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Weak Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.